Celsion (CLSN) Rating Increased to Buy at Zacks Investment Research

Celsion (NASDAQ:CLSN) was upgraded by Zacks Investment Research from a “sell” rating to a “buy” rating in a report issued on Thursday. The brokerage currently has a $3.00 target price on the biotechnology company’s stock. Zacks Investment Research‘s target price would suggest a potential upside of 7.53% from the stock’s current price.

According to Zacks, “Celsion is dedicated to the development and commercialization of oncology drugs including tumor-targeting treatments using focused heat energy in combination with heat activated drug delivery systems. Celsion has research, license or commercialization agreements with leading institutions such as the National Institutes of Health, Duke University Medical Center, University of Hong Kong, North Shore Long Island Jewish Health System. “

Get Celsion alerts:

Separately, ValuEngine upgraded Celsion from a “strong sell” rating to a “sell” rating in a research note on Wednesday, March 7th.

Shares of CLSN opened at $2.79 on Thursday. Celsion has a 52 week low of $1.24 and a 52 week high of $6.06.

Celsion (NASDAQ:CLSN) last issued its earnings results on Friday, May 11th. The biotechnology company reported ($0.25) EPS for the quarter, topping analysts’ consensus estimates of ($0.30) by $0.05. Celsion had a negative return on equity of 112.83% and a negative net margin of 3,897.86%. The firm had revenue of $0.13 million for the quarter, compared to the consensus estimate of $0.13 million. equities research analysts predict that Celsion will post -1.11 EPS for the current year.

An institutional investor recently bought a new position in Celsion stock. Virtu Financial LLC bought a new position in Celsion Co. (NASDAQ:CLSN) during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor bought 42,018 shares of the biotechnology company’s stock, valued at approximately $113,000. Virtu Financial LLC owned about 0.24% of Celsion as of its most recent SEC filing. Institutional investors own 3.91% of the company’s stock.

About Celsion

Celsion Corporation, a development stage oncology drug company, focuses on the development and commercialization of directed chemotherapy, DNA-mediated immunotherapy, and RNA based therapy products for the treatment of cancer. The company's lead product includes ThermoDox, a liposomal encapsulation of doxorubicin that is in Phase III clinical trials for primary liver cancer; and under Phase II clinical trials to treat recurrent chest wall breast cancer.

Get a free copy of the Zacks research report on Celsion (CLSN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com